80062
document
Report on the second myelomatosis trial after five years of follow-up . Medical Research Council 's Working Party on Leukaemia in Adults . Three hundred and seventy-two patients were randomized between 3 regimens of chemotherapy : cyclophosphamide , intermittent melphalan , and melphalan with prednisone , and were followed up to death or for at least 5 years . There was no difference in survival between the treatments , either overall or in any subgroup of patients . Therefore , the choice among these 3 treatments should be guided by the patient 's comfort and convenience . The most important prognostic feature at presentation was the quality of renal function . It was possible to define good , intermediate and poor renal-function groups which were highly correlated with prognosis ( X2 for trend = 62.6 ) . The haemoglobin level at presentation was strongly correlated with prognosis among patients in the good renal-function group . Among 107 patients who presented with good renal function and with haemoglobin above 100 g/l , the 5-year survival was 43 % . Other prognostic features were much less important when account was taken of renal function and haemoglobin level .
80063
Intervention_Pharmacological
3 regimens of chemotherapy : cyclophosphamide , intermittent melphalan , and melphalan with prednisone , and were followed up to death or for at least 5 years
80064
Outcome_Mortality
survival
80065
Outcome_Physical
renal function
80066
Outcome_Physical
haemoglobin level
80067
Outcome_Mortality
survival
80068
Participant_Condition
Leukaemia
80069
Participant_Age
Adults
80070
Participant_Sample-size
Three hundred and seventy-two
80071
Participant_Condition
good
80072
Participant_Condition
intermediate
80073
Participant_Condition
poor
80074
Participant_Condition
good renal-function
80075
Participant_Sample-size
107
80076
Participant_Condition
good renal function